Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Relationship between PD-L1 expression and outcome in EGFR-mutant lung cancer patients treated with EGFR tyrosine kinase inhibitors.

Lung cancer (Amsterdam, Netherlands) - 1 May 2021

Liu Jia, Itchins Malinda, Nagrial Adnan, Cooper Wendy A, De Silva Madhawa, Barnet Megan, Varikatt Winny, Sivasubramaniam Vanathi, Davis Alexander, Gill Anthony J, Blinman Prunella, Lee Kenneth, Hui Rina, Gao Bo, Pavlakis Nick, Clarke Stephen, Lee Jenny, Boyer Michael, Kao Steven

Abstract excerpt

OBJECTIVES: Predictive biomarkers for poor response to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) is an area of ongoing research. This multicentre retrospective study sought to determine the impact of programmed death-ligand 1 (PD-L1) tumour proportional score (TPS) on outcome in EGFR TKI treated patients. MATERIALS AND METHODS: Patients with Stage IIIB/IV lung adenocarcinoma...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to B7-H1 Antigen

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Drug Resistance, Neoplasm

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Mutation

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 33721613
DOI: 10.1016/j.lungcan.2021.03.004

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Relationship between PD-L1 expression and outcome in EGFR-mutant lung cancer patients treated with EGFR tyrosine kinase inhibitors.PMID 33721613Read ↗

Clinical and molecular characteristics associated with high PD-L1 expression in EGFR-mutated lung adenocarcinoma.Semantic proximity Read ↗

PD-L1 expression and its clinicopathologic and genomic correlation in the non-small cell lung carcinoma patients: An Indian perspective.Semantic proximity Read ↗

PD-L1 score as a prognostic biomarker in asian early-stage epidermal growth factor receptor-mutated lung cancer.Semantic proximity Read ↗

Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma.Semantic proximity Read ↗

PD-L1 Expression and Histopathological Features in EGFR-Mutated Non-Small Cell Lung Cancer: Implications for Immune Checkpoint Inhibitors After EGFR-Tyrosine Kinase Inhibitors Resistance.Semantic proximity Read ↗

Association of PD-L1 expression with driver gene mutations and clinicopathological characteristics in non-small cell lung cancer: A real-world study of 10 441 patients.Semantic proximity Read ↗

Prognostic impact of PD-L1 expression in surgically resected EGFR-mutant lung adenocarcinoma: A real-world database study in Japan (CReGYT-01 EGFR study).Semantic proximity Read ↗

Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors.Semantic proximity Read ↗

Revisiting Biomarker-Guided Therapy in EGFR-Mutant Non-Small Cell Lung Cancer with High PD-L1 Expression.Semantic proximity Read ↗

Impact of Programmed Death Ligand 1 Expression on Outcomes in Stage I-II Epidermal Growth Factor Receptor-Mutant Lung Adenocarcinoma.Semantic proximity Read ↗

Various impacts of driver mutations on the PD-L1 expression of NSCLC.Semantic proximity Read ↗

Clinical implications of PD-L1 expression in oncogene-driven NSCLC: Differential responses to targeted agents and immune checkpoint inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.